Sutro Biopharma (STRO) EBIT (2017 - 2025)

Sutro Biopharma (STRO) has 9 years of EBIT data on file, last reported at -$38.0 million in Q4 2025.

• For the quarter ending Q4 2025, EBIT rose 41.69% year-over-year to -$38.0 million; the trailing twelve-month figure through Dec 2025 stood at -$158.4 million (up 33.59% YoY), and the FY2025 full-year result was -$158.4 million, up 33.59% from the prior year.
• EBIT advanced to -$38.0 million in Q4 2025, from -$48.5 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $43.2 million in Q4 2023 to a low of -$68.5 million in Q1 2025.
• A 5-year average of -$35.7 million and a median of -$40.7 million in 2022 frame the typical range for EBIT.
• Across the five-year window, EBIT soared 187.67% in 2023 and tumbled 251.23% in 2024, its largest moves.
• Tracing STRO's EBIT over 5 years: stood at -$35.0 million in 2021, then plunged by 40.49% to -$49.2 million in 2022, then soared by 187.67% to $43.2 million in 2023, then plunged by 251.23% to -$65.3 million in 2024, then surged by 41.69% to -$38.0 million in 2025.
• Business Quant data shows STRO's EBIT at -$38.0 million in Q4 2025, -$48.5 million in Q3 2025, and -$3.3 million in Q2 2025.